Ringpu Bio-Technology gains approval for new feline trivalent vaccine

Ringpu Bio-Technology, along with its subsidiaries, has officially obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs for its feline trivalent inactivated vaccine. This vaccine targets feline viral rhinotracheitis, calicivirus, and panleukopenia, diseases that pose significant threats to cat health. The vaccine, comprising RPVF0304, RPVF0207, and RPVF0110 strains, was initially granted a temporary approval in January 2024.

This newly registered "Category Three" veterinary drug represents a significant advancement in pet healthcare. The company highlights the vaccine's technical advantages, including the use of highly matched antigen strains from domestic clinical samples and a four-step purification process that enhances purity and reduces animal stress. The vaccine also employs a novel water adjuvant, ensuring robust and long-lasting immunity for up to 12 months.

The successful registration underscores Ringpu Bio-Technology's commitment to technological innovation and research and development in companion animal health. The company stated this development boosts its overall competitiveness in the companion animal health sector and provides improved solutions for feline disease prevention and control. The product will require a veterinary drug product approval number before market launch, and the company is expediting the necessary applications.